The enhanced premium tax credits that kept plans affordable are set to expire at the end of this year, and if Congress ...

Median progression free survival (PFS) has not been reached in the cohort of patients with salivary gland cancer with PFS ...

The offer cmes as Senate Democrats have blocked Republicans a whopping 11 attempts to reopen the government this month alone.

Pfizer, Merck, AstraZeneca and Bristol Myers Squibb were among the many biopharmas showing off novel cancer modalities at ...

Presentation will cover two-year clinical efficacy, immunogenicity and safety dataData will be presented at an oral session on October 17, 2025, ...

Meanwhile, AstraZeneca’s Enhertu partner Daiichi arrived at ESMO armed with its own ADC data for the cadherin-6-targeting ...

The analysis of acral melanoma patients from the IGNYTE clinical trial showed treatment with RP1 combined with nivolumab resulted in an objective response rate of 44% (8/18) with a median duration of ...

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive ...

Patients with PD-L1-positive metastatic triple-negative breast cancer reported improved emotional function and pain with sacituzumab govitecan plus pembrolizumab compared with chemotherapy plus ...

A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, ...